Welcome to our dedicated page for IGC Pharma news (Ticker: IGC), a resource for investors and traders seeking the latest updates and insights on IGC Pharma stock.
IGC Pharma, Inc. develops therapeutics for Alzheimer's disease and metabolic disorders as a clinical-stage biotechnology company. News about IGC Pharma commonly centers on IGC-AD1, its cannabinoid-based lead asset in the CALMA Phase 2 trial for agitation in Alzheimer's dementia, along with pipeline programs such as TGR-63, IGC-1C and IGC-M3 targeting amyloid plaques, tau pathways, neuroinflammation and related neurodegeneration biology.
Company updates also cover the use of artificial intelligence in drug discovery and clinical-trial operations, including the Agentic Harmonization Assistant platform for biomedical data harmonization. Other recurring developments include clinical-site expansion, caregiver and patient-engagement initiatives, psilocybin research authorization in Colombia, patent activity and financial reporting.
India Globalization Capital, Inc. (NYSE American: IGC) announced the nomination of John E. Lynch as a Class A independent director, replacing Sudhakar Shenoy, at the upcoming 2020 Annual Meeting of Stockholders on January 11, 2021. Lynch, an intellectual property attorney, has been instrumental in IGC's patent strategy, helping to negotiate key patents, including those relevant to the therapeutic use of THC for Alzheimer’s. Additionally, he has served as an advisor to IGC for five years and has a strong academic background in law and chemistry.